Breaking News

Telix to Acquire QSAM Biosciences and Lead Investigational Drug

53Sm-DOTMP is aligned with Telix’s existing therapeutic focus areas in urologic oncology, neuro-oncology, and musculoskeletal oncology.

Author Image

By: Charlie Sternberg

Associate Editor

Telix has agreed to acquire QSAM Biosciences Inc.—a U.S.-based company developing therapeutic radiopharmaceuticals for primary and metastatic bone cancer—and its lead investigational drug Samarium-153-DOTMP (153Sm-DOTMP).   153Sm-DOTMP is a novel kit-based bone-seeking targeted radiopharmaceutical candidate that uses a “next generation” chelating agent to deliver a proprietary formulation of Samarium-153 radioisotope. With two major potential applications – pain management of bone metastases a...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters